Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
LA JOLLA, Calif., May 30, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.
- Jefferies 2017 Global Healthcare Conference, New York, June 6, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), company presentation and overview
- JMP Securities Life Sciences Conference, New York, June 20, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), Small Molecule Oncology Drugs: Challenges and Opportunities panel participant
A live audio webcast and replay of the presentation at the Jefferies conference will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
